Local control and outcome in children with localized vaginal rhabdomyosarcoma

A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group

David O. Walterhouse, Jane L. Meza, John C. Breneman, Sarah S. Donaldson, Andrea Hayes-Jordan, Alberto S. Pappo, Carola A.S. Arndt, R. Beverly Raney, William H. Meyer, Douglas S. Hawkins

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background: The local control approach for girls with non-resected vaginal rhabdomyosarcoma (RMS) enrolled onto Intergroup RMS Study Group (IRSG)/Children's Oncology Group (COG) studies has differed from that used at other primary sites by delaying or eliminating radiotherapy (RT) based on response achieved with chemotherapy and delayed primary resection. Procedures: We reviewed locoregional treatment and outcome for patients with localized RMS of the vagina on the two most recent COG low-risk RMS studies. Results: Forty-one patients with localized vaginal RMS were enrolled: 25 onto D9602 and 16 onto Subset 2 of ARST0331. Only four of the 39 with non-resected tumors received RT. The 5-year cumulative incidence of local recurrence was 26% on D9602, and the 2-year cumulative incidence of local recurrence was 43% on ARST0331. Increased local failure rates appeared to correlate with chemotherapy regimens that incorporated lower cumulative doses of cyclophosphamide. Estimated 5-year and 2-year failure free survival rates were 70% (95% CI: 46%, 84%) on D9602 and 42% (95% CI: 11%, 70%) on ARST0331, respectively. Conclusions: To prevent local recurrence, we recommend a local control approach for patients with non-resected RMS of the vagina that is similar to that used for other primary sites and includes RT. We recognize that potential long-term effects of RT are sometimes unacceptable, especially for children less than 24 months of age. However, when making the decision to eliminate RT, the risk of local recurrence must be considered especially when using a chemotherapy regimen with a total cumulative cyclophosphamide dose of ≤4.8g/m2.

Original languageEnglish (US)
Pages (from-to)76-83
Number of pages8
JournalPediatric Blood and Cancer
Volume57
Issue number1
DOIs
StatePublished - Jul 15 2011

Fingerprint

Rhabdomyosarcoma
Sarcoma
Radiotherapy
Recurrence
Vagina
Drug Therapy
Cyclophosphamide
Incidence
Decision Making
Survival Rate
Neoplasms

Keywords

  • Female
  • Genitourinary
  • Radiotherapy
  • Rhabdomyosarcoma
  • Vagina

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Local control and outcome in children with localized vaginal rhabdomyosarcoma : A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group. / Walterhouse, David O.; Meza, Jane L.; Breneman, John C.; Donaldson, Sarah S.; Hayes-Jordan, Andrea; Pappo, Alberto S.; Arndt, Carola A.S.; Raney, R. Beverly; Meyer, William H.; Hawkins, Douglas S.

In: Pediatric Blood and Cancer, Vol. 57, No. 1, 15.07.2011, p. 76-83.

Research output: Contribution to journalArticle

Walterhouse, DO, Meza, JL, Breneman, JC, Donaldson, SS, Hayes-Jordan, A, Pappo, AS, Arndt, CAS, Raney, RB, Meyer, WH & Hawkins, DS 2011, 'Local control and outcome in children with localized vaginal rhabdomyosarcoma: A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group', Pediatric Blood and Cancer, vol. 57, no. 1, pp. 76-83. https://doi.org/10.1002/pbc.22928
Walterhouse, David O. ; Meza, Jane L. ; Breneman, John C. ; Donaldson, Sarah S. ; Hayes-Jordan, Andrea ; Pappo, Alberto S. ; Arndt, Carola A.S. ; Raney, R. Beverly ; Meyer, William H. ; Hawkins, Douglas S. / Local control and outcome in children with localized vaginal rhabdomyosarcoma : A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group. In: Pediatric Blood and Cancer. 2011 ; Vol. 57, No. 1. pp. 76-83.
@article{bde21c55759d4887b6004a9dd385a11f,
title = "Local control and outcome in children with localized vaginal rhabdomyosarcoma: A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group",
abstract = "Background: The local control approach for girls with non-resected vaginal rhabdomyosarcoma (RMS) enrolled onto Intergroup RMS Study Group (IRSG)/Children's Oncology Group (COG) studies has differed from that used at other primary sites by delaying or eliminating radiotherapy (RT) based on response achieved with chemotherapy and delayed primary resection. Procedures: We reviewed locoregional treatment and outcome for patients with localized RMS of the vagina on the two most recent COG low-risk RMS studies. Results: Forty-one patients with localized vaginal RMS were enrolled: 25 onto D9602 and 16 onto Subset 2 of ARST0331. Only four of the 39 with non-resected tumors received RT. The 5-year cumulative incidence of local recurrence was 26{\%} on D9602, and the 2-year cumulative incidence of local recurrence was 43{\%} on ARST0331. Increased local failure rates appeared to correlate with chemotherapy regimens that incorporated lower cumulative doses of cyclophosphamide. Estimated 5-year and 2-year failure free survival rates were 70{\%} (95{\%} CI: 46{\%}, 84{\%}) on D9602 and 42{\%} (95{\%} CI: 11{\%}, 70{\%}) on ARST0331, respectively. Conclusions: To prevent local recurrence, we recommend a local control approach for patients with non-resected RMS of the vagina that is similar to that used for other primary sites and includes RT. We recognize that potential long-term effects of RT are sometimes unacceptable, especially for children less than 24 months of age. However, when making the decision to eliminate RT, the risk of local recurrence must be considered especially when using a chemotherapy regimen with a total cumulative cyclophosphamide dose of ≤4.8g/m2.",
keywords = "Female, Genitourinary, Radiotherapy, Rhabdomyosarcoma, Vagina",
author = "Walterhouse, {David O.} and Meza, {Jane L.} and Breneman, {John C.} and Donaldson, {Sarah S.} and Andrea Hayes-Jordan and Pappo, {Alberto S.} and Arndt, {Carola A.S.} and Raney, {R. Beverly} and Meyer, {William H.} and Hawkins, {Douglas S.}",
year = "2011",
month = "7",
day = "15",
doi = "10.1002/pbc.22928",
language = "English (US)",
volume = "57",
pages = "76--83",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Local control and outcome in children with localized vaginal rhabdomyosarcoma

T2 - A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group

AU - Walterhouse, David O.

AU - Meza, Jane L.

AU - Breneman, John C.

AU - Donaldson, Sarah S.

AU - Hayes-Jordan, Andrea

AU - Pappo, Alberto S.

AU - Arndt, Carola A.S.

AU - Raney, R. Beverly

AU - Meyer, William H.

AU - Hawkins, Douglas S.

PY - 2011/7/15

Y1 - 2011/7/15

N2 - Background: The local control approach for girls with non-resected vaginal rhabdomyosarcoma (RMS) enrolled onto Intergroup RMS Study Group (IRSG)/Children's Oncology Group (COG) studies has differed from that used at other primary sites by delaying or eliminating radiotherapy (RT) based on response achieved with chemotherapy and delayed primary resection. Procedures: We reviewed locoregional treatment and outcome for patients with localized RMS of the vagina on the two most recent COG low-risk RMS studies. Results: Forty-one patients with localized vaginal RMS were enrolled: 25 onto D9602 and 16 onto Subset 2 of ARST0331. Only four of the 39 with non-resected tumors received RT. The 5-year cumulative incidence of local recurrence was 26% on D9602, and the 2-year cumulative incidence of local recurrence was 43% on ARST0331. Increased local failure rates appeared to correlate with chemotherapy regimens that incorporated lower cumulative doses of cyclophosphamide. Estimated 5-year and 2-year failure free survival rates were 70% (95% CI: 46%, 84%) on D9602 and 42% (95% CI: 11%, 70%) on ARST0331, respectively. Conclusions: To prevent local recurrence, we recommend a local control approach for patients with non-resected RMS of the vagina that is similar to that used for other primary sites and includes RT. We recognize that potential long-term effects of RT are sometimes unacceptable, especially for children less than 24 months of age. However, when making the decision to eliminate RT, the risk of local recurrence must be considered especially when using a chemotherapy regimen with a total cumulative cyclophosphamide dose of ≤4.8g/m2.

AB - Background: The local control approach for girls with non-resected vaginal rhabdomyosarcoma (RMS) enrolled onto Intergroup RMS Study Group (IRSG)/Children's Oncology Group (COG) studies has differed from that used at other primary sites by delaying or eliminating radiotherapy (RT) based on response achieved with chemotherapy and delayed primary resection. Procedures: We reviewed locoregional treatment and outcome for patients with localized RMS of the vagina on the two most recent COG low-risk RMS studies. Results: Forty-one patients with localized vaginal RMS were enrolled: 25 onto D9602 and 16 onto Subset 2 of ARST0331. Only four of the 39 with non-resected tumors received RT. The 5-year cumulative incidence of local recurrence was 26% on D9602, and the 2-year cumulative incidence of local recurrence was 43% on ARST0331. Increased local failure rates appeared to correlate with chemotherapy regimens that incorporated lower cumulative doses of cyclophosphamide. Estimated 5-year and 2-year failure free survival rates were 70% (95% CI: 46%, 84%) on D9602 and 42% (95% CI: 11%, 70%) on ARST0331, respectively. Conclusions: To prevent local recurrence, we recommend a local control approach for patients with non-resected RMS of the vagina that is similar to that used for other primary sites and includes RT. We recognize that potential long-term effects of RT are sometimes unacceptable, especially for children less than 24 months of age. However, when making the decision to eliminate RT, the risk of local recurrence must be considered especially when using a chemotherapy regimen with a total cumulative cyclophosphamide dose of ≤4.8g/m2.

KW - Female

KW - Genitourinary

KW - Radiotherapy

KW - Rhabdomyosarcoma

KW - Vagina

UR - http://www.scopus.com/inward/record.url?scp=79955713549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955713549&partnerID=8YFLogxK

U2 - 10.1002/pbc.22928

DO - 10.1002/pbc.22928

M3 - Article

VL - 57

SP - 76

EP - 83

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -